Anavex Life Sciences
AVXL
141 hedge funds and large institutions have $232M invested in Anavex Life Sciences in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 16 closing their positions.
76% more call options, than puts
Call options by funds: $15.9M | Put options by funds: $9.03M
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 139 → 141 (+2)
5% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 40
0.14% more ownership
Funds ownership: 34.61% → 34.74% (+0.14%)
7% less capital invested
Capital invested by funds: $249M → $232M (-$17.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NL
NWAM LLC
Mercer Island,
Washington
|
+$5.47M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.33M |
| 4 |
Barclays
London,
United Kingdom
|
+$1.79M |
| 5 |
Citigroup
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.53M |
| 2 |
PC
Pier Capital
Stamford,
Connecticut
|
-$2.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.91M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$1.36M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Rockefeller Capital Management
New York
| – | -$25K | -2,700 | Closed |
|
|
CG
152
Cutler Group
San Francisco,
California
| – | -$13K | -1,500 | Closed |
|
|
FA
153
Fiduciary Alliance
Greenville,
South Carolina
| – | -$10.1K | -1,092 | Closed |
|
|
GFWA
154
Grey Fox Wealth Advisors
Rockland,
Delaware
| – | -$2.78K | -300 | Closed |
|
|
NA
155
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1.3K | -140 | Closed |
|
|
LSA
156
Leonteq Securities AG
Zurich,
Switzerland
| – | -$9 | -1 | Closed |
|
AVXL Hedge Fund Activity: Q1 2023 in Review
141 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q1 2023, worth a combined $232M — down 6.9% from $249M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AVXL positions and 16 closed out — a net gain of 2 holders — while 42 added to existing stakes and 40 trimmed.
The largest buyer was NWAM LLC, opening a new position worth an estimated $5.47M. The largest seller was Millennium Management, cutting an estimated $7.53M.
- 141 institutional investors held Anavex Life Sciences (AVXL) as of Q1 2023, up from 139 in Q4 2022.
- Funds reported $232M of Anavex Life Sciences stock for Q1 2023, down 6.9% quarter-over-quarter.
- 18 funds opened new Anavex Life Sciences positions in Q1 2023 and 16 closed out, a net change of +2 holders.
- The largest Anavex Life Sciences buyer in Q1 2023 was NWAM LLC, an estimated $5.47M added.
- The largest Anavex Life Sciences seller in Q1 2023 was Millennium Management, an estimated $7.53M sold.
Based on aggregated 13F filings for Q1 2023.